TLRY
Tilray Brands, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$2.50
−5.27%Research · Apr 23, 2026
Trump's Reported Marijuana Reclassification: Tilray Rally Just Beginning?
Tilray leads cannabis surge on Trump reclassification reports confirming Schedule III path. Upside of 20-30% TLRY, 15-25% CGC, 10-20% ACB over 3 days as banking and tax relief unlock. Breaks on report retraction or congressional punt by July.